Intelligencia AI
Intelligencia AI™ leads the way in leveraging proprietary data, biomedical expertise and AI with its patented technology to address significant challenges in the pharmaceutical industry: lengthy drug development timelines, excessive costs and unsustainable return on investment. ZS leverages Intelligencia AI’s purpose-built and harmonized data along with its flagship solution, Portfolio Optimizer™, to support pharma teams with data and insights.
Partnership Impact
ZS and Intelligencia AI help clients make confident, data-backed decisions to reduce risk in clinical development pipelines.
100+
Projects using Intelligencia AI data for portfolio, pipeline and business development decisions
>80%
Accuracy of predicted PTRS* assessments across all clinical development phases
* Probability of technical and regulatory success.
Delivering Results
Partnership and value
Our clients benefit from our synergistic relationship and ability to use Intelligencia Portfolio Optimizer.
Industry expertise
A deep and comprehensive dataset with over 50 billion data points updated weekly, curated by therapeutic area experts to ensure relevance and accuracy.
Scalable solution
Portfolio Optimizer fits into workflows to augment and enhance processes and methodologies for assessing drug portfolios and to inform go/no-go decisions, identify licensing and acquisition targets earlier and assess the competitive landscape.
Actionable insights
Forward-looking, AI-driven PTRS assessments offer valuable insights to inform and enhance decision-making confidence.
Data-driven precision
Intelligencia AI’s proprietary and patented algorithms have demonstrated elevated levels of accuracy in predicting success and are continually refined with additional data, along with AI to show the drivers behind the how and why of the predictions.
OUR IMPACT
Helping a global pharma company accelerate business development decisions in oncology
Intelligencia AI and ZS collaborated to support a global pharmaceutical company’s strategy and business development team. ZS reviewed the oncology market and identified assets for potential in-licensing or co-development for its China division.
OUR IMPACT
Elevate and de-risk your drug portfolio strategy with AI
In this on-demand webinar, discover how data-driven insights and AI can reduce risks in drug development. Industry leaders share how using AI for PTRS validation, asset prioritization and strategic decisions helps achieve their business goals.
- 1
- 2
Insights
In the news
Talk to Us
Learn more about our partnerships
Related solutions
Artificial Intelligence
Compliance, Privacy & Risk
Analytics
